How CytoAgents’ plans for growth run far beyond Covid crisis
GP1681 “has the potential to be the next best practice in medicine in areas with significant unmet need,” CytoAgents CEO Teresa Whalen said. Out clinical trials as well as plans for growth to include other uses for the dreuge. CytoAgents is working in Australia with its partner, Novotech, on the phase one clinical trial of GP1681…Read more >>